SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ron who wrote (756)5/7/1999 4:46:00 PM
From: yosi s  Read Replies (3) of 1386
 
That is where you are wrong.
If Q1 number are consistent with projected growth and becoming a + cash flow company at year end.
then it will have a + impact.
No news for HU 211 partner until summer.
Not so far away after all.
As for approval of Alrex and Lotemax in Europe.
BOL got to do that some times this year.
I also expect some info about Canada and the rest of the world.. for marketing Alrex and Lotemax.
And some news for Le Tobra.

There is also plans to begin clinical on Tamoxiphen analog.
So if revenues numbers are good. Better chances to get that study going.
Also progress with Cohort 3 of phase 2.

All of the above may have an answer with a conference call Tuesday...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News